
Loading, please wait...

Loading, please wait...

Viral myocarditis remains a significant clinical challenge for cardiologists globally. It often leads to severe complications like dilated cardiomyopathy and heart failure. Recent research has shed light on CVB3 viral myocarditis pathogenesis, specifically focusing on how Coxsackievirus B3 (CVB3) subverts host cellular defenses. Single-cell RNA sequencing reveals a strong link between impaired mitophagy and cardiomyocyte damage during infection. Mitophagy, the selective removal of damaged mitochondria via the PINK1 pathway, typically maintains cardiac health. However, CVB3 successfully disrupts this mechanism to facilitate its own survival.
In the context of CVB3 viral myocarditis pathogenesis, the non-structural protein 3C plays a destructive role. This viral protease promotes the degradation of the mitochondrial antiviral signaling protein, known as MAVS. Importantly, MAVS interacts directly with PINK1 to form a regulatory loop. When 3C degrades MAVS, PINK1 levels also decline. This deficiency prevents the cell from clearing dysfunctional mitochondria. Consequently, the accumulation of damaged mitochondria creates an environment that favors viral replication and worsens myocardial injury. Furthermore, the transcription factor FOSL1 has emerged as a negative regulator of PINK1. FOSL1 binds directly to the PINK1 promoter, further silencing its expression during infection.
The identification of the 3C/FOSL1/PINK1/MAVS signaling axis provides a roadmap for future interventions. Since current treatments for viral myocarditis are largely supportive, these findings suggest that restoring mitochondrial homeostasis could be a viable therapeutic strategy. Specifically, protecting PINK1 from transcriptional suppression or preventing 3C-mediated MAVS degradation may limit viral spread. Additionally, enhancing mitophagy could potentially preserve cardiomyocyte function and prevent the progression toward heart failure. These insights offer hope for targeted therapies that go beyond traditional antiviral approaches.
PINK1 is a protein kinase that initiates mitophagy. It identifies damaged mitochondria and marks them for degradation. This process ensures that cardiomyocytes maintain efficient energy production and avoid oxidative stress.
CVB3 uses its 3C protease to degrade MAVS and suppress PINK1. By disabling these proteins, the virus prevents the host's innate immune response and disrupts mitochondrial quality control, which allows the virus to replicate more efficiently.
FOSL1 acts as a transcription factor that inhibits the production of PINK1. During a CVB3 infection, FOSL1 levels can increase, leading to reduced PINK1 expression and further impairing the cell\'s ability to perform essential mitophagy.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Liu T et al. 3C suppresses PINK1-mediated mitophagy and contributes to coxsackievirus B3 replication. Virulence. 2026 Dec undefined. doi: 10.1080/21505594.2026.2662767. PMID: 42035472.
Kim H et al. Critical roles of parkin and PINK1 in coxsackievirus B3-induced viral myocarditis. Institut Pasteur. 2023 Aug 11. doi: 10.1016/j.micinf.2023.105191.
Zhang J et al. Role of Coxsackievirus B3-Induced Immune Responses in the Transition from Myocarditis to Dilated Cardiomyopathy and Heart Failure. PMC. 2023 Apr 23. doi: 10.3390/v15051034.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New research identifies the 3C/FOSL1/PINK1/MAVS signaling axis as a primary driver of CVB3 replication and cardiomyocyte pathology in viral myocarditis....
4 months ago

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today